Statement of Changes in Beneficial Ownership (4)
11 August 2020 - 9:26AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Rohlen Douglas |
2. Issuer Name and Ticker or Trading Symbol
Eidos Therapeutics, Inc.
[
EIDX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2000 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
8/6/2020 |
(Street)
SAN FRANCISCO, CA 94104
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Restricted Stock Units | (1) | 8/6/2020 | | A | | 4526 | | (2) | (2) | Common Stock | 4526 | $0.00 | 4526 | D | |
Stock Option (Right to Buy) | $41.42 | 8/6/2020 | | A | | 21447 | | (3) | 8/5/2030 | Common Stock | 21447 | $0.00 | 21447 | D | |
Explanation of Responses: |
(1) | Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
(2) | The shares of Common Stock underlying the RSUs vest in three annual installments after the date of grant, subject to the Reporting Person's continued service on the Issuer's board of directors as of each vesting date. |
(3) | The stock option shall vest in three annual installments after the date of grant, subject to the Reporting Person's continued service on the Issuer's board of directors as of each vesting date. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Rohlen Douglas C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2000 SAN FRANCISCO, CA 94104 | X |
|
|
|
Signatures
|
/s/ Franco Valle, as Attorney-in-Fact | | 8/10/2020 |
**Signature of Reporting Person | Date |
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Apr 2024 to May 2024
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Eidos Therapeutics Inc (NASDAQ): 0 recent articles
More Eidos Therapeutics, Inc. News Articles